- Sup material description[supplements/278314_file08.docx]
- SuppFig1[supplements/278314_file09.pdf]
- SuppFig2[supplements/278314_file10.pdf]
- SuppFig3[supplements/278314_file11.pdf]
- SuppFig4[supplements/278314_file12.pdf]
- SuppFig5[supplements/278314_file13.pdf]
- SuppFig6[supplements/278314_file14.pdf]
- SuppFig7[supplements/278314_file15.pdf]
- SuppFig8[supplements/278314_file16.pdf]
- SuppFig9[supplements/278314_file17.pdf]
- SuppTable1[supplements/278314_file18.xlsx]
- SuppTable2[supplements/278314_file19.xlsx]
- SuppTable3[supplements/278314_file20.xlsx]
- SuppTable4[supplements/278314_file21.xlsx]
- SuppTable5[supplements/278314_file22.xlsx]
- SuppTable6[supplements/278314_file23.xlsx]
- SuppTable7[supplements/278314_file24.xlsx]
- SuppTable8[supplements/278314_file25.xlsx]
- SuppTable9[supplements/278314_file26.xlsx]
- SuppTable10[supplements/278314_file27.xlsx]
- SuppTable11[supplements/278314_file28.xlsx]
- SuppTable12[supplements/278314_file29.xlsx]
Posted August 03, 2022.
MULTI-OMICS TEMPORAL PROFILING OF AXIAL SPONDYLOARTHRITIS PATIENTS REVEALS AN ASSOCIATION OF THERAPEUTIC RESPONSE TO ADALIMUMAB WITH DISEASE ACTIVITY AND INNATE / ADAPTIVE IMMUNITY
